Cargando…

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies

BACKGROUND: Several different Physician Global Assessment (PGA) versions have been used in clinical studies as a co-primary end point to evaluate psoriasis severity. Tofacitinib is an oral Janus kinase inhibitor. We performed an analysis of the PGA using data from studies of tofacitinib in moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Callis Duffin, Kristina, Bushmakin, Andrew G., Cappelleri, Joseph C., Mallbris, Lotus, Mamolo, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555979/
https://www.ncbi.nlm.nih.gov/pubmed/31174539
http://dx.doi.org/10.1186/s12895-019-0088-2
_version_ 1783425249597980672
author Callis Duffin, Kristina
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Mallbris, Lotus
Mamolo, Carla
author_facet Callis Duffin, Kristina
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Mallbris, Lotus
Mamolo, Carla
author_sort Callis Duffin, Kristina
collection PubMed
description BACKGROUND: Several different Physician Global Assessment (PGA) versions have been used in clinical studies as a co-primary end point to evaluate psoriasis severity. Tofacitinib is an oral Janus kinase inhibitor. We performed an analysis of the PGA using data from studies of tofacitinib in moderate to severe chronic plaque psoriasis. METHODS: Data from 3641 patients with moderate to severe chronic plaque psoriasis, enrolled in one of four phase III tofacitinib studies (OPT Pivotal 1 and 2, OPT Compare and OPT Retreatment), were used to evaluate a three-item PGA scale. RESULTS: Confirmatory Factor Analyses showed that equal weighting of the three items (erythema, induration and scaling) was appropriate. The PGA demonstrated acceptable test–retest reliability (Intraclass Correlation Coefficient, 0.7) and internal consistency (Cronbach’s Coefficient Alpha ≥ 0.9 at primary time points). The Clinically Important Difference was estimated as 0.55 (95% confidence interval: 0.546–0.563). Known-group validity was shown by demonstrating that PGA scores could discriminate between different degrees of disease severity. The PGA was significantly correlated with other clinical end points in the studies (Psoriasis Area and Severity Index, r = 0.75–0.79; Dermatology Life Quality Index, r = 0.44–0.57; Patient Global Assessment, r = 0.66–0.72). CONCLUSIONS: Consistent with previous findings from a phase II study, these results indicate that this PGA is a valid, reliable instrument for evaluating disease severity in clinical studies of psoriasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12895-019-0088-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6555979
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65559792019-06-10 A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies Callis Duffin, Kristina Bushmakin, Andrew G. Cappelleri, Joseph C. Mallbris, Lotus Mamolo, Carla BMC Dermatol Research Article BACKGROUND: Several different Physician Global Assessment (PGA) versions have been used in clinical studies as a co-primary end point to evaluate psoriasis severity. Tofacitinib is an oral Janus kinase inhibitor. We performed an analysis of the PGA using data from studies of tofacitinib in moderate to severe chronic plaque psoriasis. METHODS: Data from 3641 patients with moderate to severe chronic plaque psoriasis, enrolled in one of four phase III tofacitinib studies (OPT Pivotal 1 and 2, OPT Compare and OPT Retreatment), were used to evaluate a three-item PGA scale. RESULTS: Confirmatory Factor Analyses showed that equal weighting of the three items (erythema, induration and scaling) was appropriate. The PGA demonstrated acceptable test–retest reliability (Intraclass Correlation Coefficient, 0.7) and internal consistency (Cronbach’s Coefficient Alpha ≥ 0.9 at primary time points). The Clinically Important Difference was estimated as 0.55 (95% confidence interval: 0.546–0.563). Known-group validity was shown by demonstrating that PGA scores could discriminate between different degrees of disease severity. The PGA was significantly correlated with other clinical end points in the studies (Psoriasis Area and Severity Index, r = 0.75–0.79; Dermatology Life Quality Index, r = 0.44–0.57; Patient Global Assessment, r = 0.66–0.72). CONCLUSIONS: Consistent with previous findings from a phase II study, these results indicate that this PGA is a valid, reliable instrument for evaluating disease severity in clinical studies of psoriasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12895-019-0088-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-07 /pmc/articles/PMC6555979/ /pubmed/31174539 http://dx.doi.org/10.1186/s12895-019-0088-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Callis Duffin, Kristina
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Mallbris, Lotus
Mamolo, Carla
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
title A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
title_full A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
title_fullStr A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
title_full_unstemmed A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
title_short A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
title_sort multi-item physician global assessment scale to assess psoriasis disease severity: validation based on four phase iii tofacitinib studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555979/
https://www.ncbi.nlm.nih.gov/pubmed/31174539
http://dx.doi.org/10.1186/s12895-019-0088-2
work_keys_str_mv AT callisduffinkristina amultiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT bushmakinandrewg amultiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT cappellerijosephc amultiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT mallbrislotus amultiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT mamolocarla amultiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT callisduffinkristina multiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT bushmakinandrewg multiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT cappellerijosephc multiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT mallbrislotus multiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies
AT mamolocarla multiitemphysicianglobalassessmentscaletoassesspsoriasisdiseaseseverityvalidationbasedonfourphaseiiitofacitinibstudies